ES2173420T3 - Comprimidos que contienen un antibiotico de beta-lactamico y procedimiento para su produccion. - Google Patents

Comprimidos que contienen un antibiotico de beta-lactamico y procedimiento para su produccion.

Info

Publication number
ES2173420T3
ES2173420T3 ES97904616T ES97904616T ES2173420T3 ES 2173420 T3 ES2173420 T3 ES 2173420T3 ES 97904616 T ES97904616 T ES 97904616T ES 97904616 T ES97904616 T ES 97904616T ES 2173420 T3 ES2173420 T3 ES 2173420T3
Authority
ES
Spain
Prior art keywords
tablets containing
lactamic
procedure
production
antibiotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97904616T
Other languages
English (en)
Spanish (es)
Inventor
Hisami Yamaguchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2173420T3 publication Critical patent/ES2173420T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Seasonings (AREA)
ES97904616T 1996-02-29 1997-02-21 Comprimidos que contienen un antibiotico de beta-lactamico y procedimiento para su produccion. Expired - Lifetime ES2173420T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4274396 1996-02-29
JP32026496 1996-11-29

Publications (1)

Publication Number Publication Date
ES2173420T3 true ES2173420T3 (es) 2002-10-16

Family

ID=26382481

Family Applications (2)

Application Number Title Priority Date Filing Date
ES97904616T Expired - Lifetime ES2173420T3 (es) 1996-02-29 1997-02-21 Comprimidos que contienen un antibiotico de beta-lactamico y procedimiento para su produccion.
ES01123407T Expired - Lifetime ES2231369T3 (es) 1996-02-29 1997-02-21 Granulo de disgregacion rapida de un edulcorante sintetico que contiene acido silicico y/o dioxido de silicio.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES01123407T Expired - Lifetime ES2231369T3 (es) 1996-02-29 1997-02-21 Granulo de disgregacion rapida de un edulcorante sintetico que contiene acido silicico y/o dioxido de silicio.

Country Status (23)

Country Link
US (4) US6423341B1 (enrdf_load_stackoverflow)
EP (2) EP1166651B1 (enrdf_load_stackoverflow)
JP (1) JP3180350B2 (enrdf_load_stackoverflow)
KR (1) KR20040058360A (enrdf_load_stackoverflow)
CN (2) CN1136853C (enrdf_load_stackoverflow)
AR (1) AR006012A1 (enrdf_load_stackoverflow)
AT (2) ATE216887T1 (enrdf_load_stackoverflow)
AU (1) AU724946B2 (enrdf_load_stackoverflow)
BR (1) BR9707780A (enrdf_load_stackoverflow)
CA (1) CA2248179C (enrdf_load_stackoverflow)
DE (2) DE69732312T8 (enrdf_load_stackoverflow)
DK (2) DK1166651T3 (enrdf_load_stackoverflow)
EA (1) EA001089B1 (enrdf_load_stackoverflow)
ES (2) ES2173420T3 (enrdf_load_stackoverflow)
HU (1) HU227821B1 (enrdf_load_stackoverflow)
IL (1) IL125214A0 (enrdf_load_stackoverflow)
MX (1) MX9806265A (enrdf_load_stackoverflow)
NZ (2) NZ512609A (enrdf_load_stackoverflow)
PT (2) PT890359E (enrdf_load_stackoverflow)
TR (1) TR199801680T2 (enrdf_load_stackoverflow)
TW (1) TW473393B (enrdf_load_stackoverflow)
WO (1) WO1997031639A1 (enrdf_load_stackoverflow)
ZA (1) ZA971584B (enrdf_load_stackoverflow)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6746105B2 (en) 1997-07-15 2004-06-08 Silverbrook Research Pty. Ltd. Thermally actuated ink jet printing mechanism having a series of thermal actuator units
US5948440A (en) * 1997-12-17 1999-09-07 Ranbaxy Laboratories Limited Modified release matrix formulation of cefaclor and cephalexin
CA2587022A1 (en) 1998-05-18 1999-11-25 Takeda Pharmaceutical Company Limited Orally disintegrable tablets
US7399485B1 (en) 1998-07-28 2008-07-15 Takeda Pharmaceutical Company Limited Rapidly Disintegrable solid preparation
US20070160675A1 (en) * 1998-11-02 2007-07-12 Elan Corporation, Plc Nanoparticulate and controlled release compositions comprising a cephalosporin
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
AR025976A1 (es) * 1999-10-08 2002-12-26 Affinium Pharm Inc Inhibidores de fab i.
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
FR2814679B1 (fr) * 2000-09-29 2003-04-11 Cll Pharma Compositions pharmaceutiques dispersibles a base de cephalosporines, leur procede de preparation et leur utilisation
EP1560584B1 (en) * 2001-04-06 2009-01-14 Affinium Pharmaceuticals, Inc. Fab i inhibitors
GB0123400D0 (en) * 2001-09-28 2001-11-21 Novartis Ag Organic compounds
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
TW200404550A (en) * 2002-07-08 2004-04-01 Sankyo Co Cepharospolin formulation for oral use
JP4526247B2 (ja) * 2002-07-08 2010-08-18 第一三共株式会社 経口用セファロスポリン製剤
KR20110005727A (ko) * 2002-08-13 2011-01-18 산도즈 아게 세프디니르 중간체
CA2508792C (en) * 2002-12-06 2013-02-05 Affinium Pharmaceuticals, Inc. Heterocyclic compounds, methods of making them and their use in therapy
EP1608377B1 (en) * 2003-03-17 2008-10-01 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
KR20050121209A (ko) * 2003-03-24 2005-12-26 에이씨에스 도브파 에스. 피. 에이. 7-[2-(2-아미노티아졸-4-일)-2-하이드록시이미노아세트아미도-3-비닐-3-세펨-4-카복실산(신 이성체)의 신규 결정 및이의 제조방법
JP4505859B2 (ja) * 2003-08-08 2010-07-21 味の素株式会社 ナテグリニド含有製剤
US20050113355A1 (en) * 2003-09-12 2005-05-26 Duerst Richard W. Cefdinir pyridine salt
US20050059818A1 (en) * 2003-09-12 2005-03-17 Duerst Richard W. Polymorph of a pharmaceutical
US20050059819A1 (en) * 2003-09-12 2005-03-17 Duerst Richard W. Cefdinir pyridine salt
JP2005162696A (ja) * 2003-12-04 2005-06-23 Nichiko Pharmaceutical Co Ltd 溶出性に優れたセフジトレンピボキシル製剤
US20080139528A1 (en) * 2003-12-10 2008-06-12 Pujara Chetan P Cefdinir oral suspension
US20050131079A1 (en) * 2003-12-10 2005-06-16 Pujara Chetan P. Cefdinir oral suspension
US20060142563A1 (en) * 2004-03-16 2006-06-29 Devalina Law Crystalline anhydrous cefdinir and crystalline cefdinir hydrates
US20060211676A1 (en) * 2004-03-16 2006-09-21 Devalina Law Crystalline anhydrous cefdinir and crystalline cefdinir hydrates
US20060142261A1 (en) * 2004-03-16 2006-06-29 Devalina Law Crystalline anhydrous cefdinir and crystalline cefdinir hydrates
US20060069079A1 (en) * 2004-09-27 2006-03-30 Sever Nancy E Stable amorphous cefdinir
BRPI0418769A (pt) 2004-05-10 2007-10-09 Lupin Ltd composição farmacêutica compreendendo cefixima, processo para a preparação de uma forma de dosagem oral sólida compreendendo de partìculas de cefixima, método para conseguir bio-equivalência entre a forma de dosagem oral e uma suspensão e comprimido mastigável compreendendo cefixima
JP2006527064A (ja) * 2004-05-31 2006-11-30 サンア ファーマシューティカルス カンパニー リミテッド β−ラクタム系抗生物質を含む懸濁錠剤及びその製造方法
EP1828167B1 (en) * 2004-06-04 2014-08-06 Debiopharm International SA Acrylamide derivatives as antibiotic agents
US20060099253A1 (en) * 2004-10-20 2006-05-11 Wyeth Antibiotic product formulation
IL169678A (en) 2005-07-14 2010-11-30 Innova Sa Sweetener compositions
US20090156578A1 (en) * 2005-12-05 2009-06-18 PAULS Henry 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents
US20070128268A1 (en) * 2005-12-07 2007-06-07 Herwig Jennewein Pharmaceutical compositions comprising an antibiotic
US20090197855A1 (en) * 2006-05-01 2009-08-06 Makarand Krishnakumar Avachat Pharmaceutical compositions of cefdinir
WO2008009122A1 (en) 2006-07-20 2008-01-24 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as fab i inhibitors
US20110201814A1 (en) * 2006-12-07 2011-08-18 Daiichi Sankyo Company Limited Method for producing solid preparation
KR101506043B1 (ko) 2006-12-07 2015-03-25 다이이찌 산쿄 가부시키가이샤 저치환도 히드록시프로필셀룰로오스를 함유하는 의약 조성물
CA2672134C (en) * 2006-12-07 2015-02-10 Daiichi Sankyo Company, Limited Solid medicinal preparation containing mannitol or lactose
WO2008098374A1 (en) * 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
TR200909785A1 (tr) * 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.
TR200909786A1 (tr) * 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Sefiksim içeren efervesan tablet ve granül formülasyonu.
US8614315B2 (en) 2009-12-25 2013-12-24 Mahmut Bilgic Cefdinir and cefixime formulations and uses thereof
EP2515859B1 (en) * 2009-12-25 2015-09-16 Mahmut Bilgic Rapidly dispersing effervescent formulation
TR201000686A1 (tr) * 2010-01-29 2011-08-22 B�Lg�� Mahmut Bakteriyel enfeksiyonların tedavisinde suda çözünebilir sefdinir ve klavulanik asit formülasyonları.@
TR201000687A1 (tr) * 2010-01-29 2011-08-22 Bi̇lgi̇ç Mahmut Aktif madde olarak sefiksim ve klavulanik asit içeren efervesan formülasyonlar
TR201001417A1 (tr) * 2010-02-25 2011-09-21 Sanovel İlaç San. Ve Ti̇c. A. Ş. Geliştirilmiş çözünme hızına sahip sefdinir formülasyonu
EP2566448B1 (en) * 2010-05-04 2015-06-17 Mahmut Bilgic Efervescent formulations comprising cefdinir
WO2011142731A2 (en) * 2010-05-14 2011-11-17 Mahmut Bilgic Formulations comprising a third generation cephalosporin and clavulanic acid
EA021874B1 (ru) * 2010-09-13 2015-09-30 ЛИМОНОВ, Виктор Львович Фармацевтическая композиция антимикробного действия для парентерального введения и способ ее получения
TR201009166A2 (tr) * 2010-11-05 2012-05-21 Bi̇lgi̇ç Mahmut Sefdinir içeren farmasötik bileşim için üretim yöntemi
TR201010212A2 (tr) * 2010-12-08 2012-06-21 Bi̇lgi̇ç Mahmut Sefdinir içeren katı oral dozaj formu.
BR122021020778B1 (pt) 2012-06-19 2022-07-12 Debiopharm International Sa Derivados de pró-fármaco de (e)-n-metil-n-((3-metilbenzofuran-2-il) metil)-3-(7-oxo-5,6,7,8-tetraidro- 1, 8- naftirindin-3-il) acrilamida
WO2014051532A1 (en) * 2012-09-28 2014-04-03 Bilgic Mahmut Pharmaceutical tablet formulations comprising cefdinir
WO2014053468A1 (en) * 2012-10-02 2014-04-10 Montero Gida Sanayi Ve Ticaret A.S. Mogroside formulation and a production process thereof
EP2906203B1 (en) 2012-10-11 2018-01-03 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Effervescent cefdinir formulation
EP2815743A1 (en) 2013-06-21 2014-12-24 Sanovel Ilac Sanayi ve Ticaret A.S. Ceftibuten formulations
US10231476B2 (en) 2014-04-04 2019-03-19 Douxmatok Ltd Sweetener compositions and foods, beverages, and consumable products made thereof
US10207004B2 (en) 2014-04-04 2019-02-19 Douxmatok Ltd Method for producing sweetener compositions and sweetener compositions
US20160242439A1 (en) 2014-04-04 2016-08-25 Douxmatok Ltd Method for producing sweetener compositions and sweetener compositions
AU2017223037B2 (en) 2016-02-26 2022-04-14 Debiopharm International S.A. Medicament for treatment of diabetic foot infections
US12403131B2 (en) 2019-02-14 2025-09-02 Debiopharm International S.A. Afabicin formulation, method for making the same and uses thereof
CN115607514B (zh) * 2021-07-16 2023-12-12 广州白云山天心制药股份有限公司 一种含有头孢地尼颗粒的制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3098749A (en) * 1960-11-16 1963-07-23 Abbott Lab Sweetening agent and process of producing the same
US3336199A (en) * 1963-07-03 1967-08-15 Warner Lambert Pharmaceutical Tablet composition
DE2251250C3 (de) * 1972-10-19 1981-06-25 Hoechst Ag, 6230 Frankfurt Verfahren zur Herstellung hochdosierter Antibiotica-Tabletten
US4039673A (en) * 1973-10-30 1977-08-02 Bayer Aktiengesellschaft Penicillins and cephalosporins and their production
JPS5438167B2 (enrdf_load_stackoverflow) * 1974-04-27 1979-11-19
US4248894A (en) * 1979-01-17 1981-02-03 Life Savers, Inc. Long-lasting flavored chewing gum containing non-sugar sweetener codried on chalk or other filler and method
US4384005A (en) * 1980-09-26 1983-05-17 General Foods Corporation Non-friable, readily-soluble, compressed tablets and process for preparing same
JPS57150361A (en) * 1981-03-10 1982-09-17 Ajinomoto Co Inc Granule of dipeptide sweetener
US4352821A (en) * 1981-07-21 1982-10-05 Shaklee Corporation Sweet tableting agent
EP0080862B1 (en) * 1981-12-02 1985-09-25 Beecham Group Plc Pharmaceutical formulation comprising beta-lactam antibiotics
JPS58198268A (ja) * 1982-05-14 1983-11-18 Ajinomoto Co Inc 甘味料顆粒又はキユ−ブの製造法
US4600579A (en) * 1983-06-07 1986-07-15 Mallinckrodt, Inc. N-acetyl-p-aminophenol compositions containing partially gelatinized starch and method for preparing same
US4752485A (en) * 1984-10-05 1988-06-21 Warner-Lambert Company Novel sweetener delivery systems
US4722845A (en) * 1986-12-23 1988-02-02 Warner-Lambert Company Stable cinnamon-flavored chewing gum composition
ES2061623T3 (es) * 1987-03-02 1994-12-16 Brocades Pharma Bv Procedimiento para la obtencion de una composicion farmaceutica y un granulado farmaceutico.
US4915948A (en) * 1987-08-31 1990-04-10 Warner-Lambert Company Tablets having improved bioadhesion to mucous membranes
JPH01206969A (ja) * 1987-10-30 1989-08-21 Takeda Chem Ind Ltd 甘味料顆粒の製造法
JPH01149728A (ja) * 1987-12-04 1989-06-12 Fujisawa Pharmaceut Co Ltd 抗潰瘍剤
FR2634355B1 (fr) * 1988-07-25 1990-09-14 Beghin Say Sa Nouveau produit edulcorant alimentaire a base de saccharose et d'edulcorant intense et son procede de preparation
US5085876A (en) * 1988-11-16 1992-02-04 The Nutrasweet Company Fast dissolving sweetening agent including caramel
US5114929A (en) * 1989-03-21 1992-05-19 Beecham Group P.L.C. Pharmaceutical formulation
FR2669221B1 (fr) * 1990-11-15 1993-01-15 Rhone Poulenc Sante Procede de preparation par compression directe de comprimes de derives de l'acide cephalosporanique.
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
ATE216577T1 (de) * 1992-01-29 2002-05-15 Takeda Chemical Industries Ltd Schnellösliche tablette und ihre herstellung
ES2059260B1 (es) * 1992-10-06 1995-04-16 Espanola Prod Quimicos Procedimiento de preparacion de comprimidos conteniendo diclofenaco; dispersables en agua.
JP3063438B2 (ja) * 1992-12-24 2000-07-12 田辺製薬株式会社 ドパミン誘導体含有経口投与用製剤
KR0177894B1 (ko) * 1993-07-28 1999-03-20 아만 히데아키 항우울제
DE4418957A1 (de) * 1994-05-31 1995-12-07 Merck Patent Gmbh Cefixim-Zubereitung
JP2994956B2 (ja) * 1994-05-31 1999-12-27 信越化学工業株式会社 低置換度ヒドロキシプロピルセルロース、その組成物およびその錠剤
ES2082723B1 (es) * 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
FR2722984B1 (fr) * 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.

Also Published As

Publication number Publication date
EP0890359B1 (en) 2002-05-02
HK1015684A1 (en) 1999-10-22
CN1409995A (zh) 2003-04-16
EP0890359A4 (enrdf_load_stackoverflow) 1999-01-13
DE69732312T8 (de) 2006-07-27
TR199801680T2 (xx) 1999-02-22
DE69712332D1 (de) 2002-06-06
ATE287218T1 (de) 2005-02-15
CA2248179C (en) 2007-09-18
HU227821B1 (en) 2012-03-28
JP3180350B2 (ja) 2001-06-25
EA199800775A1 (ru) 1999-02-25
DE69732312T2 (de) 2006-04-06
NZ512609A (en) 2003-03-28
ZA971584B (en) 1997-09-10
EP0890359A1 (en) 1999-01-13
DK1166651T3 (da) 2005-05-30
US20030129227A1 (en) 2003-07-10
PT890359E (pt) 2003-03-31
CN1136853C (zh) 2004-02-04
HUP9901877A1 (hu) 1999-12-28
AR006012A1 (es) 1999-07-21
KR20040058360A (ko) 2004-07-03
ES2231369T3 (es) 2005-05-16
EA001089B1 (ru) 2000-10-30
CN1212626A (zh) 1999-03-31
TW473393B (en) 2002-01-21
ATE216887T1 (de) 2002-05-15
AU724946B2 (en) 2000-10-05
HUP9901877A3 (en) 2000-04-28
CA2248179A1 (en) 1997-09-04
EP1166651B1 (en) 2005-01-19
MX9806265A (es) 1998-12-31
BR9707780A (pt) 1999-07-27
AU1734797A (en) 1997-09-16
US6423341B1 (en) 2002-07-23
PT1166651E (pt) 2005-04-29
US20070134325A1 (en) 2007-06-14
DE69712332T2 (de) 2002-10-02
US20020051816A1 (en) 2002-05-02
IL125214A0 (en) 1999-03-12
NZ330864A (en) 2001-07-27
US20020192281A1 (en) 2002-12-19
DE69732312D1 (de) 2005-02-24
EP1166651A1 (en) 2002-01-02
WO1997031639A1 (fr) 1997-09-04
DK0890359T3 (da) 2002-07-01

Similar Documents

Publication Publication Date Title
ES2173420T3 (es) Comprimidos que contienen un antibiotico de beta-lactamico y procedimiento para su produccion.
NO993520L (no) Doseringsformer og fremgangsmÕte for Õ bedre erektil dysfunksjon
IL176452A0 (en) Effervescent oral opiate dosage form
HRP20010632A2 (en) Matrix tablet enabling prolonged release of gliclazide after administration by the oral route
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
DE69941115D1 (de) Tablette mit einzelnem kern zur oralen verabreichung mit kontrollierter freisetzung
ATE252379T1 (de) Orale pharmazeutische dosierungsform beruhend auf stossweiser freisetzung
CY2347B1 (en) Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route.
TR200100931T2 (tr) Yeni sürekli salınımlı oral formülasyonlar
ES2132216T3 (es) Nuevos derivados de amidinas, su preparacion y utilizacion como medicamentos con efecto antagonista de ltb4.
DK1259240T3 (da) Midler, såsom nikotinamid eller CADPR, til behandling af hudsygdomme
TR200101719T2 (tr) Erkeklerde organik ereksiyona bağlı işlev bozukluğunun tedavisi için ilaç imalatında apomorfin kullanımı
DE69826019D1 (de) Feste dispergierende impfstoffe-zusammensetzung zur oralen verabreichung
EE200100388A (et) Püridasino [4,5-b] indool-1-atseetamiidi derivaatide kasutamine ravimite valmistamiseks perifeersete bensodiasepiiniretseptorite düsfunktsioneerimisega seotud haiguste raviks
DE602004003577D1 (de) Schwimmende orale formulierungen mit kontrollierter freisetzung von betain
DE60017175D1 (de) Ciclesonidhaltige arzneizusammensetzung zur verabreichung auf die schleimhäute
RS50246B (sr) Tableta za sisanje, koja sadrži ambroksol
IL157539A0 (en) A stable pharmaceutical formulation comprising torsemide modification ii
AR007058A1 (es) Uso de interferon en medicamentos y composiciones para contacto oromucosal
DK0927031T3 (da) Farmaceutisk sammensætning indeholdende nimesulid til oral admnistration
AU3064501A (en) Water dispersed ivermectin dosage form used for curing ecto- and endoparasitic diseases
ATE230998T1 (de) Arzneimittel zur manipulation der t-zell immunantwort
EG22658A (en) Matrix tablet enabling prolonged release of gliclazide after administration by the oral route
TW200611686A (en) Effervescent oral opiate dosage forms and methods of administering opiates
IT1274592B (it) Composizione farmaceutica per la terapia tumorale contenente xenoantigeni

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 890359

Country of ref document: ES